Files and links (2)
Published VersionCC BY V4.0, Open Access
Journal article
Caerin 1.1/1.9 Enhances Antitumour Immunity by Activating the IFN-α Response Signalling Pathway of Tumour Macrophages
Cancers, Vol.14(23), pp.1-22
2022
PMID: 36497272
Abstract
Macrophages are one of the essential components of the tumour microenvironment (TME) of many cancers and show complex heterogeneity and functions. More recent research has been focusing on the characterisation of tumour-associated macrophages (TAMs). Previously, our study demonstrated that caerin 1.1/1.9 peptides significantly improve the therapeutic efficacy of combined specific immunotherapy and immune checkpoint blockade in a murine transplantable tumour model (TC-1). In this study, the mice inoculated with TC-1 tumour were immunised differently. The TAMs were isolated using flow cytometry and characterised by cytokine ELISA. The survival rates of mice with different treatments containing caerin 1.1/19 were assessed comparatively, including those with/without macrophage depletion. The single-cell RNA sequencing (scRNA-seq) data of previous studies were integrated to further reveal the functions of TAMs with the treatments containing caerin 1.1/1.9. As a comparison, the TAMs of stage I and II cervical cancer patients were analysed using scRNA-seq analysis. We demonstrate that caerin induced tumour clearance is associated with infiltration of tumours by IL-12 secreting Ly6C+F4/80+ macrophages exhibiting enhanced IFN-α response signalling, renders animals resistant to further tumour challenge, which is lost after macrophage depletion. Our results indicate that caerin 1.1/1.9 treatment has great potential in improving current immunotherapy efficacy.
Details
- Title
- Caerin 1.1/1.9 Enhances Antitumour Immunity by Activating the IFN-α Response Signalling Pathway of Tumour Macrophages
- Authors
- Xiaodan Yang (Author) - Guangdong Pharmaceutical UniversityXiaosong Liu (Author) - First People's Hospital of FoshanJunjie Li (Author) - Guangdong Pharmaceutical UniversityPingping Zhang (Author) - First People's Hospital of FoshanHejie Li (Author) - University of the Sunshine Coast, Queensland, School of Science, Technology and EngineeringGuoqiang Chen (Author) - First People's Hospital of FoshanWei Zhang (Author) - Guangdong Pharmaceutical UniversityTianfang Wang (Author) - University of the Sunshine Coast, Queensland, School of Science, Technology and EngineeringIan Frazer (Author) - The University of QueenslandGuoying Ni (Corresponding Author) - First People's Hospital of Foshan
- Publication details
- Cancers, Vol.14(23), pp.1-22
- Publisher
- MDPI AG
- Date published
- 2022
- DOI
- 10.3390/cancers14235785
- ISSN
- 2072-6694
- PMID
- 36497272
- Copyright note
- © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- Grant note
- 2019A008 / Deng Feng project of Foshan First People's Hospital 2015AG1003 / Foshan Municipal Government 2016A020213001 / Guangdong Science and Technology Department 31971355 / National Natural Science Foundation of China 2020A1515010855 / Natural Science Foundation of Guangdong Province of China
- Organisation Unit
- School of Science and Engineering - Legacy; GeneCology Research Centre - Legacy; School of Science, Technology and Engineering; Centre for Bioinnovation
- Language
- English
- Record Identifier
- 99696657402621
- Output Type
- Journal article
Metrics
185 File views/ downloads
38 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Oncology
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites